COO
The Cooper Companies, Inc.
COO has slightly lower modeled downside risk, despite its lower overall score.
LLY
Eli Lilly and Company
LLY has the edge over COO overall, supported by stronger fundamentals and stronger modeled upside.
COO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Stable |
COO's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
COO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 13x | $62.19 | — |
| Cheap | 17x | $50.37 | -19% |
| Current | 21x | $62.19 | — |
| Fair | 40x | $117 | +89% |
| Expensive | 61x | $179 | +189% |
Historical ranges are pointers, not guarantees.
COO has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
COO Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect COO's earnings to grow and its profitability to improve, with its revenue holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over COO on the outlook, with more favorable revenue expectations.
COO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.64 | +59% |
| Q3 2026 | $2.92 | +43% |
| Q2 2026 | $1.17 | -43% |
| Q1 2026 | $2.01 | -2.9% |
| Q4 2025 | $1.87 | -4.6% |
| Q3 2025 | $2.04 | +14% |
| Q2 2025 | $2.07 | +22% |
| Q1 2025 | $2.07 | +42% |
| Q4 2024 | $1.96 | +32% |
COO's earnings per share have fallen from their peak: $2.92 over the past year, against $14.79 in late 2021.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over COO on earnings, with more consistent year-over-year improvement.
COO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +0.6% |
| Q2 2026 | $1.1B | +7.9% |
| Q1 2026 | $1B | +6.2% |
| Q4 2025 | $1.1B | +4.6% |
| Q3 2025 | $1.1B | +5.7% |
| Q2 2025 | $1B | +6.3% |
| Q1 2025 | $964.7M | +3.6% |
| Q4 2024 | $1B | +9.8% |
COO's revenue has grown year over year for 23 quarters in a row: $1.1B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | +4.3 points |
| Q2 2026 | -2.9% | -21 points |
| Q1 2026 | 21% | +1.9 points |
| Q4 2025 | 13% | -6.3 points |
| Q3 2025 | 17% | -2.6 points |
| Q2 2025 | 18% | +1.3 points |
| Q1 2025 | 19% | +2.4 points |
| Q4 2024 | 19% | +4.8 points |
COO's operating margin was 21% last quarter, up 4.3 points from the same quarter a year ago, near the top of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over COO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over COO on profitability, with a higher operating margin.
COO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $273M | +66% |
| Q2 2026 | $96.4M | +433% |
| Q1 2026 | $158.7M | +57% |
| Q4 2025 | $149.9M | +17% |
| Q3 2025 | $164.5M | +39% |
| Q2 2025 | $18.1M | -51% |
| Q1 2025 | $101.2M | +2100% |
| Q4 2024 | $128.1M | +339% |
COO has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
COO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -1.6M shares |
| 1 year | -3.3% | -6.6M shares |
| 3 years | -3.1% | -6.2M shares |
| 5 years | -2.9% | -5.8M shares |
| Available history | -3.3% | -6.6M shares |
COO has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $339.2M |
| Q2 2026 | $15.5M |
| Q1 2026 | $92.5M |
| Q4 2025 | $196.8M |
| Q3 2025 | $52.7M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
COO spent $644M buying back its own shares over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
COO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.6x | Moderate |
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 2.1x | Moderate |
| Q2 2025 | 2.2x | Moderate |
| Q1 2025 | 2.2x | Moderate |
| Q4 2024 | 2.3x | Moderate |
COO's net debt is about 2.6 years of its operating earnings (EBITDA), up from 2.1 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over COO on leverage, with a lower net debt burden relative to earnings.
COO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.3 | Neutral |
| Stochastic | 38.2 | Neutral |
COO's weekly RSI is 46 (neutral) and its Stochastic is 38 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
COO PE vs Healthcare Sector
| Metric | COO | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 18% below |
| PE % | 22 | 29 | 7 pts below |
COO has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
COO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $58.7 | 5.9% above |
| 20 week MA | $65.3 | 4.7% below |
| 50 week MA | $70.3 | 12% below |
| 100 week MA | $74.3 | 16% below |
| 200 week MA | $83.9 | 26% below |
COO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 26% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over COO on trend strength, trading above more of its moving averages.
COO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $80.3 | $89.6 | +12% |
| 2021 | $89.6 | $102.8 | +15% |
| 2022 | $102.8 | $83.2 | -19% |
| 2023 | $83.2 | $94.6 | +14% |
| 2024 | $94.6 | $92.3 | -2.4% |
| 2025 | $92.3 | $82.6 | -11% |
| 2026 YTD | $82.6 | $62.2 | -25% |
COO has finished lower in three of the last six years. It's down 25% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over COO on returns for 2026, with the stronger performance.